NATIONAL-TSING-HUA-UNIV
4.3.2020 10:02:08 CET | Business Wire | Press release
Although unmanned aerial vehicles (UAV) are commonly used in the fields such as communications and agriculture, their use is hampered by their small size and limited battery capacity. However, a multi-disciplinary team at National Tsing Hua University led by professors Tang Kea-tiong of the Department of Electrical Engineering and Lo Chung-chuan of the Department of Life Sciences has recently developed an artificial intelligence (AI) chip that mimics the optical nerves of the fruit fly, allowing drones to automatically avoid obstacles while remaining in an ultra-power-saving mode.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200304005029/en/
Most of the UAVs currently in use rely on the transmission and reflection of electromagnetic waves to detect and avoid obstacles, but this consumes a lot of power. An alternative approach to avoiding obstacles is to use optical lenses to capture and analyze images, but the amount of information to be processed is too large to be done quickly, and this approach also consumes much power.
Intrigued by the fruit fly’s uncanny ability to avoid obstacles, Tang figured that it might be possible to replicate the optical nerve of this tiny insect and adapt it to AI applications.
The first task was to solve the problem of information overload. According to Tang, the image sensor currently used in cameras and mobile phones have millions of pixels, whereas the eye of a fruit fly has only about 800 pixels. When the fruit fly’s brain processes such visual signals as contour and contrast, it utilizes a kind of detection mechanism which automatically filters out unimportant information, and only pays attention to moving objects liable to collide with.
By imitating this detection mechanism, the research team has developed an AI chip which makes it possible to use hand gestures and an image sensor to operate a drone.
First the drone is taught to focus on what’s most important, and then it’s taught how to judge distance and the likelihood of a collision. For this purpose, Lo conducted a detailed investigation on how the fruit fly detects optical flow, for which purpose he made extensive use of the maps of the fruit fly’s neural pathways produced by the Brain Research Center at NTHU. “Optical flow is the relative trajectory left in the field of vision by nearby moving objects, and which is used by the brain to determine its distance and to avoid obstacles,” Lo explained.
Tang said that the AI chip developed by his research team represents a major breakthrough in the area of in-memory computing. Computers and mobile phones first move data from the memory to the CPU’s central processing unit, and once it’s processed, the data is moved back to the memory for storage, and such a process is what consumes up to 90% of the energy and time of the AI deep-learning process. By contrast, the AI chip developed by the NTHU team mimics neuronal synapses, allowing it to perform computations in the memory, which greatly improves efficiency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200304005029/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
